Compare TH & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | URGN |
|---|---|---|
| Founded | 1978 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2017 | 2016 |
| Metric | TH | URGN |
|---|---|---|
| Price | $16.13 | $40.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $16.50 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 1.1M | 782.4K |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $320,635,000.00 | $1,128,000.00 |
| Revenue This Year | $17.45 | $129.09 |
| Revenue Next Year | $38.19 | $70.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.97 | $15.86 |
| 52 Week High | $20.85 | $43.93 |
| Indicator | TH | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 63.35 |
| Support Level | $15.95 | $18.23 |
| Resistance Level | $16.12 | N/A |
| Average True Range (ATR) | 0.69 | 2.11 |
| MACD | -0.22 | -0.05 |
| Stochastic Oscillator | 1.17 | 61.79 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.